Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2020

01-12-2020 | Glucocorticoid | Research article

Long-term changes in renal function after treatment initiation and the importance of early diagnosis in maintaining renal function among IgG4-related tubulointerstitial nephritis patients in Japan

Authors: Haruna Arai, Soshiro Ogata, Takaya Ozeki, Kazuo Takahashi, Naotake Tsuboi, Shoichi Maruyama, Daijo Inaguma, Midori Hasegawa, Yukio Yuzawa, Hiroki Hayashi

Published in: Arthritis Research & Therapy | Issue 1/2020

Login to get access

Abstract

Background

The present study aimed to investigate associations between long-term renal function, whether IgG4-related tubulointerstitial nephritis (TIN) was diagnosed by renal biopsy at initial examination, chronic kidney disease (CKD) stage, and histological stage in patients with IgG4-related TIN.

Methods

This study used a retrospective cohort design including almost all patients who underwent renal biopsy at Fujita Health University Hospital and Nagoya University or its affiliated hospitals in Aichi between April 2003 and March 2015 (n = 6977 renal biopsies). The primary outcome was longitudinal changes in eGFR. Main exposures were whether IgG4-related TIN was diagnosed by renal biopsy at the initial examination, CKD stage, and its histological stage. Linear mixed models were performed to examine associations.

Results

Of the 6977 samples, there were 24 patients (with 201 records due to repeated measures) with IgG4-related TIN (20 men, mean age, 68.7 ± 9.7 years). They were followed up 6.6 ± 2.8 years after the renal biopsy and underwent glucocorticoid treatment. We found significant increase in eGFR from the baseline to 2 and 6 months after treatment initiation, which was maintained until 60 months. Patients initially diagnosed with IgG4-related TIN had higher eGFR from the baseline (at the start of treatment) to 60 months than those who were not. Compared with patients with CKD stage 3, patients with CKD stages 4 and 5 had lower eGFR at the baseline and other time points. Patients with histological stage B had comparatively lower eGFR at each point than stage A patients. Those mean differences of eGFR were stable from the baseline to 60 months.

Conclusions

After the treatment initiation, renal function rapidly improved and maintained for a long period, even with advanced CKD stage. We showed importance of early diagnosis of IgG4-related TIN in maintaining eGFR.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rheumatology M, Ky AS. Comprehensive diagnostic criteria for IgG4-related disease ( IgG4-RD ), 2011. Mod Rheumatol. 2012;22:21–30.CrossRef Rheumatology M, Ky AS. Comprehensive diagnostic criteria for IgG4-related disease ( IgG4-RD ), 2011. Mod Rheumatol. 2012;22:21–30.CrossRef
2.
go back to reference Yamaguchi Y, Kanetsuna Y, Honda K, Yamanaka N, Kawano M, Nagata M, et al. Characteristic tubulointerstitial nephritis in IgG4-related disease. Hum Pathol. 2012;43:536–49.CrossRefPubMed Yamaguchi Y, Kanetsuna Y, Honda K, Yamanaka N, Kawano M, Nagata M, et al. Characteristic tubulointerstitial nephritis in IgG4-related disease. Hum Pathol. 2012;43:536–49.CrossRefPubMed
3.
go back to reference Stone JH, Brito-Zerón P, Bosch X, Ramos-Casals M. Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc. 2015;90:927–39.CrossRefPubMed Stone JH, Brito-Zerón P, Bosch X, Ramos-Casals M. Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc. 2015;90:927–39.CrossRefPubMed
4.
go back to reference Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.CrossRefPubMed Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.CrossRefPubMed
6.
go back to reference Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38:982–4.CrossRefPubMed Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38:982–4.CrossRefPubMed
7.
go back to reference Yamamoto M, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, Takahashi H, et al. Elevated IgG4 concentrations in serum of patients with Mikulicz’s disease. Scand J Rheumatol. 2004;33:432–3.CrossRefPubMed Yamamoto M, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, Takahashi H, et al. Elevated IgG4 concentrations in serum of patients with Mikulicz’s disease. Scand J Rheumatol. 2004;33:432–3.CrossRefPubMed
8.
go back to reference Deshpande V, Zen Y, Chan JKC, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181–92.CrossRefPubMed Deshpande V, Zen Y, Chan JKC, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181–92.CrossRefPubMed
9.
go back to reference Saeki T, Nishi S, Imai N, Ito T, Yamazaki H, Kawano M, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 2010;78:1016–23.CrossRefPubMed Saeki T, Nishi S, Imai N, Ito T, Yamazaki H, Kawano M, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 2010;78:1016–23.CrossRefPubMed
10.
go back to reference Kawano M, Saeki T, Nakashima H, Nishi S, Yamaguchi Y, Hisano S, et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol. 2011;15:615–26.CrossRefPubMed Kawano M, Saeki T, Nakashima H, Nishi S, Yamaguchi Y, Hisano S, et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol. 2011;15:615–26.CrossRefPubMed
11.
go back to reference Raissian Y, Nasr SH, Larsen CP, Colvin RB, Smyrk TC, Takahashi N, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol. 2011;22:1343–52.CrossRefPubMedPubMedCentral Raissian Y, Nasr SH, Larsen CP, Colvin RB, Smyrk TC, Takahashi N, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol. 2011;22:1343–52.CrossRefPubMedPubMedCentral
12.
go back to reference Nishi S, Imai N, Yoshida K, Ito Y, Saeki T. Clinicopathological findings of immunoglobulin G4-related kidney disease. Clin Exp Nephrol. 2011;15:810–9. Nishi S, Imai N, Yoshida K, Ito Y, Saeki T. Clinicopathological findings of immunoglobulin G4-related kidney disease. Clin Exp Nephrol. 2011;15:810–9.
14.
go back to reference Saeki T, Kawano M, Mizushima I, Yamamoto M, Wada Y, Nakashima H, et al. The clinical course of patients with IgG4-related kidney disease. Kidney Int Nature Publishing Group. 2013;84:826–33.CrossRef Saeki T, Kawano M, Mizushima I, Yamamoto M, Wada Y, Nakashima H, et al. The clinical course of patients with IgG4-related kidney disease. Kidney Int Nature Publishing Group. 2013;84:826–33.CrossRef
15.
go back to reference Nishi S, Imai N, Yoshida K, Ito Y, Saeki T. Clinicopathological findings of immunoglobulin G4-related kidney disease. Clin. Exp. Nephrol.2011;15:810–819. Nishi S, Imai N, Yoshida K, Ito Y, Saeki T. Clinicopathological findings of immunoglobulin G4-related kidney disease. Clin. Exp. Nephrol.2011;15:810–819.
16.
go back to reference Mizushima I, Yamada K, Fujii H, Inoue D, Umehara H, Yamagishi M, et al. Clinical and histological changes associated with corticosteroid therapy in IgG4-related tubulointerstitial nephritis. Mod Rheumatol. 2012;22:859–70.CrossRefPubMedPubMedCentral Mizushima I, Yamada K, Fujii H, Inoue D, Umehara H, Yamagishi M, et al. Clinical and histological changes associated with corticosteroid therapy in IgG4-related tubulointerstitial nephritis. Mod Rheumatol. 2012;22:859–70.CrossRefPubMedPubMedCentral
17.
go back to reference Arai H, Hayashi H, Takahashi K, Koide S, Sato W, Hasegawa M, et al. Tubulointerstitial fibrosis in patients with IgG4-related kidney disease: pathological findings on repeat renal biopsy. Rheumatol Int. 2015;35:1093–101.CrossRefPubMed Arai H, Hayashi H, Takahashi K, Koide S, Sato W, Hasegawa M, et al. Tubulointerstitial fibrosis in patients with IgG4-related kidney disease: pathological findings on repeat renal biopsy. Rheumatol Int. 2015;35:1093–101.CrossRefPubMed
18.
go back to reference Saeki T, Kawano M, Mizushima I, Yamamoto M, Wada Y, Ubara Y, et al. Recovery of renal function after glucocorticoid therapy for IgG4-related kidney disease with renal dysfunction. Clin Exp Nephrol Springer Tokyo. 2016;20:87–93.CrossRef Saeki T, Kawano M, Mizushima I, Yamamoto M, Wada Y, Ubara Y, et al. Recovery of renal function after glucocorticoid therapy for IgG4-related kidney disease with renal dysfunction. Clin Exp Nephrol Springer Tokyo. 2016;20:87–93.CrossRef
19.
go back to reference Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, et al. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep Nature. 2018;8. Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, et al. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep Nature. 2018;8.
20.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis WB Saunders. 2009;53:982–92.CrossRef Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis WB Saunders. 2009;53:982–92.CrossRef
21.
22.
go back to reference Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using latent classes and latent processes: the {R} package {lcmm}. J Stat Softw. 2017;78:1–56.CrossRef Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using latent classes and latent processes: the {R} package {lcmm}. J Stat Softw. 2017;78:1–56.CrossRef
23.
go back to reference core Team R. R: a language and environment for statistical computing. R Found Stat Comput Vienna, Austria. 2018;. core Team R. R: a language and environment for statistical computing. R Found Stat Comput Vienna, Austria. 2018;.
24.
go back to reference Mizushima I, Yamamoto M, Inoue D, Nishi S, Taniguchi Y, Ubara Y, et al. Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study. Arthritis Res Ther; 2016;18:1–9. Mizushima I, Yamamoto M, Inoue D, Nishi S, Taniguchi Y, Ubara Y, et al. Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study. Arthritis Res Ther; 2016;18:1–9.
25.
go back to reference Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–15.CrossRefPubMed Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–15.CrossRefPubMed
26.
go back to reference Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M, et al. Evaluation and management of autoimmune pancreatitis: experience at a large us center. Am J Gastroenterol. 2009;104:2295–306.CrossRefPubMedPubMedCentral Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M, et al. Evaluation and management of autoimmune pancreatitis: experience at a large us center. Am J Gastroenterol. 2009;104:2295–306.CrossRefPubMedPubMedCentral
27.
go back to reference Fernández-Codina A, Martínez-Valle F, Pinilla B, López C, De Torres I, Solans-Laqué R, et al. IgG4-related disease: results from a multicenter Spanish registry. Med (United States). Lippincott Williams and Wilkins; 2015;94. Fernández-Codina A, Martínez-Valle F, Pinilla B, López C, De Torres I, Solans-Laqué R, et al. IgG4-related disease: results from a multicenter Spanish registry. Med (United States). Lippincott Williams and Wilkins; 2015;94.
28.
go back to reference Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62:1607–15.CrossRefPubMed Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62:1607–15.CrossRefPubMed
29.
go back to reference Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74:1171–7.CrossRefPubMed Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74:1171–7.CrossRefPubMed
30.
go back to reference Quattrocchio G, Barreca A, Demarchi A, Solfietti L, Beltrame G, Fenoglio R, et al. IgG4-related kidney disease: the effects of a rituximab-based immunosuppressive therapy. Oncotarget. 2018;9:21337–47.CrossRefPubMedPubMedCentral Quattrocchio G, Barreca A, Demarchi A, Solfietti L, Beltrame G, Fenoglio R, et al. IgG4-related kidney disease: the effects of a rituximab-based immunosuppressive therapy. Oncotarget. 2018;9:21337–47.CrossRefPubMedPubMedCentral
Metadata
Title
Long-term changes in renal function after treatment initiation and the importance of early diagnosis in maintaining renal function among IgG4-related tubulointerstitial nephritis patients in Japan
Authors
Haruna Arai
Soshiro Ogata
Takaya Ozeki
Kazuo Takahashi
Naotake Tsuboi
Shoichi Maruyama
Daijo Inaguma
Midori Hasegawa
Yukio Yuzawa
Hiroki Hayashi
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2020
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-020-02320-x

Other articles of this Issue 1/2020

Arthritis Research & Therapy 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.